血清神經(jīng)生長(zhǎng)因子及細(xì)胞免疫水平在乳腺癌中的表達(dá)及其與臨床病理特征的相關(guān)性

王文慧 溫媛媛 陳豪

[摘要] 目的 探討血清神經(jīng)生長(zhǎng)因子（NGF）及細(xì)胞免疫水平在乳腺癌患者中的表達(dá)及其與臨床病理特征的相關(guān)性。 方法 選擇2015年3月～2018年2月在杭州市婦產(chǎn)科醫(yī)院及浙江省舟山醫(yī)院確診的乳腺癌患者49例，設(shè)為觀察組;選擇同期入院的乳腺良性疾病患者45例，設(shè)為對(duì)照組;選擇同期入院健康體檢女性47名，設(shè)為正常組。采用酶聯(lián)免疫吸附試驗(yàn)測(cè)定各組NGF表達(dá)水平;采用流式細(xì)胞儀測(cè)定各組CD3+、CD4+、CD8+及CD4+/CD8+水平;記錄并統(tǒng)計(jì)患者臨床病理資料，分析各組和觀察組乳腺癌不同臨床病理資料的NGF、細(xì)胞免疫水平;采用Pearson分析NGF、細(xì)胞免疫水平與乳腺癌患者臨床病理資料的相關(guān)性。 結(jié)果 三組NGF、細(xì)胞免疫水平比較，差異均有統(tǒng)計(jì)學(xué)意義（P < 0.05）。觀察組NGF水平高于對(duì)照組與正常組，且對(duì)照組NGF水平高于正常組，差異均有統(tǒng)計(jì)學(xué)意義（P < 0.05）。觀察組CD3+、CD4+及CD4+/CD8+水平低于對(duì)照組與正常組，CD8+水平高于對(duì)照組與正常組，差異均有統(tǒng)計(jì)學(xué)意義（P < 0.05）;對(duì)照組與正常組CD3+、CD4+、CD8+及CD4+/CD8+水平比較，差異無(wú)統(tǒng)計(jì)學(xué)意義（P > 0.05）。乳腺癌組織中NGF、CD3+、CD4+、CD8+及CD4+/CD8+水平在年齡、病理組織學(xué)類型方面比較，差異無(wú)統(tǒng)計(jì)學(xué)意義（P > 0.05）;乳腺癌組織中NGF、CD3+、CD4+、CD8+及CD4+/CD8+水平在腫瘤最大徑、病理分級(jí)、分化程度及淋巴結(jié)轉(zhuǎn)移方面比較，差異均有統(tǒng)計(jì)學(xué)意義（P < 0.05）;Pearson相關(guān)性分析顯示：NGF、CD8+水平與腫瘤最大徑、病理分級(jí)、分化程度及淋巴結(jié)轉(zhuǎn)移呈正相關(guān)（P < 0.05）;CD3+、CD4+及CD4+/CD8+水平與腫瘤最大徑病理分級(jí)、分化程度及淋巴結(jié)轉(zhuǎn)移呈負(fù)相關(guān)（P < 0.05）。 結(jié)論 NGF在乳腺癌患者中呈高表達(dá)，導(dǎo)致機(jī)體細(xì)胞免疫水平下降，且二者表達(dá)水平與病理特征具有相關(guān)性，加強(qiáng)NGF及細(xì)胞免疫水平測(cè)定能評(píng)估患者疾病嚴(yán)重程度，指導(dǎo)臨床治療。

[關(guān)鍵詞] 血清神經(jīng)生長(zhǎng)因子;細(xì)胞免疫水平;乳腺癌;病理特征;相關(guān)性;酶聯(lián)免疫吸附試驗(yàn);流式細(xì)胞儀

[中圖分類號(hào)] R737.9 ? ? ? ? ?[文獻(xiàn)標(biāo)識(shí)碼] A ? ? ? ? ?[文章編號(hào)] 1673-7210（2020）04（b）-0088-05

Expression of serum nerve growth factor and cellular immunity in breast cancer and its correlation with clinicopathological feature

WANG Wenhui1 ? WEN Yuanyuan2 ? CHEN Hao1

1.Department of Pathology， Hangzhou Maternity Hospital， Zhejiang Province， Hangzhou ? 310008， China; 2.Pathological Diagnosis Center， Zhejiang Zhoushan Hospital， Zhejiang Province， Zhoushan ? 316021， China

[Abstract] Objective To investigate the expression of serum nerve growth factor （NGF） and cellular immunity in breast cancer patients and its correlation with clinicopathological feature. Methods A total of 49 breast cancer patients diagnosed in Hangzhou Maternity Hospital and Zhejiang Zhoushan Hospital from March 2015 to February 2018 were selected as the observation group. A total of 45 patients with benign breast disease who were hospitalized at the same time were selected as the control group. A total of 47 female patients with physical examination at the same time were selected as the normal group. The expression levels of NGF in each group were determined by enzyme-linked immunosorbent assay. The levels of CD3+， CD4+， CD8+ and CD4+/CD8+ in each group were determined by flow cytometry. The clinicopathological data of the patients were recorded and counted. The levels of NGF and cellular immunity in each group and the levels of NGF and cellular immunity in different clinicopathological data of breast cancer in the observation group were analyzed. The correlation between NGF， cellular immunity level and clinicopathological data of breast cancer patients was analyzed by Pearson analysis. Results The levels of NGF and cellular immunity in the three groups were statistically significant （P < 0.05）. The level of NGF in the observation group was higher than that in the control group and the normal group， and the level of NGF in the control group was higher than that in the normal group， with statistically significant differences （P < 0.05）. The levels of CD3+， CD4+ and CD4+/CD8+ in the observation group were lower than those in the control group and the normal group， and the level of CD8+ was higher than that in the control group and the normal group， with statistically significant differences （P < 0.05）. There was no significant difference in the levels of CD3+， CD4+， CD8+ and CD4+/CD8+ between the control group and the normal group （P > 0.05）. The levels of NGF， CD3+， CD4+， CD8+ and CD4+/CD8+ in breast cancer tissues were not statistically significant differences in terms of age and histopathological type （P > 0.05）. The levels of NGF， CD3+， CD4+， CD8+ and CD4+/CD8+ in breast cancer tissues were compared in terms of tumor maximum diameter， pathological grading， differentiation degree and lymph node metastasis， with statistically significant differences （P < 0.05）. The Pearson correlation analysis results showed that the NGF and CD8+ levels were positively correlated with the maximum tumor diameter， pathological grading， differentiation degree and lymph node metastasis （P < 0.05）. The levels of CD3+， CD4+ and CD4+/CD8+ were negatively correlated with the maximum tumor diameter， pathological grading， differentiation degree and lymph node metastasis （P < 0.05）. Conclusion The high expression of NGF in breast cancer patients leads to the decline of cellular immunity level in the body， and the expression level of both is correlated with the pathology feature. Strengthening the determination of NGF and cellular immunity level can assess the severity of the disease in patients and guide clinical treatment.

乳腺癌的發(fā)生發(fā)展是一個(gè)多因素過(guò)程，常伴有細(xì)胞免疫水平的變化[16-17]。研究表明[18-19]，腫瘤患者外周血腫細(xì)胞免疫水平常呈低表達(dá)。CD4+T細(xì)胞能調(diào)控局部炎癥與細(xì)胞毒相關(guān)的免疫應(yīng)答，能促進(jìn)機(jī)體產(chǎn)生抗體;此外，CD4+T細(xì)胞還能活化自然殺傷細(xì)胞與巨噬細(xì)胞，提高巨噬細(xì)胞的殺傷能力;CD8+T細(xì)胞毒性相對(duì)較輕，在殺死腫瘤細(xì)胞中發(fā)揮了重要的作用。研究表明[20-21]，細(xì)胞免疫對(duì)于腫瘤免疫反應(yīng)的抑制能在淋巴組織中表現(xiàn)，能種植效應(yīng)細(xì)胞活化階段，改變腫瘤的微環(huán)境，從而干擾機(jī)體正常的抗腫瘤免疫應(yīng)答，抑制腫瘤細(xì)胞的清除。乳腺癌患者中細(xì)胞免疫水平受影響因素較多，包括腫瘤的分期、腫瘤大小、分化程度等。本研究中，分析結(jié)果顯示：NGF、CD8+水平與腫瘤最大徑、病理分級(jí)、分化程度及淋巴結(jié)轉(zhuǎn)移呈正相關(guān)（P < 0.05）;CD3+、CD4+及CD4+/CD8+水平與腫瘤最大徑、病理分級(jí)、分化程度及淋巴結(jié)轉(zhuǎn)移呈負(fù)相關(guān)（P < 0.05）?？梢?jiàn)乳腺癌患者中細(xì)胞免疫水平與病理表現(xiàn)存在相關(guān)性。為了提高乳腺癌患者診斷、治療效果，可加強(qiáng)患者NGF和細(xì)胞免疫水平測(cè)定，評(píng)估患者疾病嚴(yán)重程度;對(duì)于確診的乳腺癌患者盡早給予手術(shù)、放化療等治療，且治療過(guò)程中加強(qiáng)患者NGF和細(xì)胞免疫水平測(cè)定能評(píng)估患者預(yù)后，可以視檢測(cè)結(jié)果調(diào)整治療方案，使得患者的治療更具科學(xué)性[22]。

綜上所述，NGF在乳腺癌患者中呈高表達(dá)，導(dǎo)致機(jī)體細(xì)胞免疫水平下降，且二者表達(dá)水平與病理表現(xiàn)具有相關(guān)性，加強(qiáng)NGF及細(xì)胞免疫水平測(cè)定能評(píng)估患者疾病嚴(yán)重程度，指導(dǎo)臨床治療。

[參考文獻(xiàn)]

[1] ?張季，李楊，楊思原，等.乳腺癌患者血清神經(jīng)生長(zhǎng)因子和低親和力受體p75表達(dá)水平的變化及其意義[J].中國(guó)普通外科雜志，2017，26（11）：1498-1501.

[2] ?李福喜，邵文鳳，唐芮，等.埃茲蛋白477位酪氨酸的磷酸化在神經(jīng)生長(zhǎng)因子前體促進(jìn)乳腺癌細(xì)胞侵襲中起關(guān)鍵作用[J].南方醫(yī)科大學(xué)學(xué)報(bào)，2016，36（7）：898-903.

[3] ?Zhu J，Zhang XR，Yang H. Effects of combined epidural and general anesthesia on intraoperative hemodynamic responses，postoperative cellular immunity，and prognosis in patients with gallbladder cancer：A randomized controlled trial [J]. Medicine（Baltimore），2017，96（10）：e6137.

[4] ?吳立春，谷仕艷，代黃梅，等.長(zhǎng)鏈非編碼RNA-ROR在乳腺癌患者血清、癌組織中的表達(dá)變化及其臨床意義[J].山東醫(yī)藥，2017，57（32）：78-80.

[5] ?Xiao Z，Wang C，Sun Y，et al. Can Aidi injection restore cellular immunity and improve clinical efficacy in non-small-cell lung cancer patients treated with platinum-based chemotherapy. A meta-analysis of 17 randomized controlled trials following the PRISMA guidelines [J]. Medicine（Baltimore），2016，95（44）：e5210.

[6] ?Chen X，Yin B，Lian RC，et al. Modulatory effects of vitamin D on peripheral cellular immunity in patients with recurrent miscarriage [J]. Am J Reprod Immunol，2016，76（6）：432-438.

[7] ?王松，薛文華，趙曉玉，等.多西他賽、表柔比星聯(lián)合環(huán)磷酰胺對(duì)不同分子分型乳腺癌患者臨床療效及腫瘤標(biāo)志物表達(dá)的影響[J].中國(guó)藥房，2017，28（23）：3212-3216.

[8] ?劉玉芳，李琳，許巖壘，等.三黃煎劑聯(lián)合新輔助化療對(duì)乳腺癌的近期療效及對(duì)Survivin及Ki-67表達(dá)的影響[J].中藥材，2016，39（9）：2143-2146.

[9] ?Gruber IV，Hartkopf AD，Hahn M，et al. Relationship Between Hematogenous Tumor Cell Dissemination and Cellular Immunity in DCIS Patients [J]. Anticancer Res，2016， 36（5）：2345-2351.

[10] ?Lundgren S，Lyden E，Burdorf A，et al. Left ventricular assist device does not improve cellular immunity in end-stage heart failure[J]. J A Coll Cardiol，2018，71（11）：A950.

[11] ?Grifoni A，Angelo M，Sidney J，et al. Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 （Tonga/74）Support Its Suitability as a Human Dengue Virus Challenge Strain [J]. J Virol，2017，91（8）. pii：e02133-16.

[12] ?李杰寶，喻曉程，田野，等.果蠅zeste基因增強(qiáng)子同源物2在乳腺癌組織中的表達(dá)及其與乳腺癌分子分型的相關(guān)性[J].中華實(shí)驗(yàn)外科雜志，2016，33（9）：2196-2199.

[13] ?王博，王宇，胡少軍，等.卡培他濱聯(lián)合多西他賽對(duì)乳腺癌肝轉(zhuǎn)移患者血管內(nèi)皮生長(zhǎng)因子、肝細(xì)胞生長(zhǎng)因子及預(yù)后的影響[J].中國(guó)免疫學(xué)雜志，2017，33（11）：1706-1708，1712.

[14] ?錢朋飛，張樹(shù)平，鄧素華，等.尿多酸肽聯(lián)合化療對(duì)乳腺癌患者免疫功能的影響[J].中華腫瘤防治雜志，2016， 23（19）：1307-1311.

[15] ?張楠，孫剛，馬斌林.散發(fā)性乳腺癌患者乳腺癌易感基因1mRNA與蛋白的表達(dá)變化差異及意義[J].中華實(shí)驗(yàn)外科雜志，2016，33（4）：884-887.

[16] ?Khaled AR，Limaye A，Bassiouni R，et al. Abstract P4-04-12：Enhancing the immunogenicity of breast cancer cells to stimulate innate immunity and augment the effects of cellular immunotherapy [J]. Cancer Res，2016，76（4 Supplement）：P4-04-12-P4-04-12.

[17] ?金妍.細(xì)胞免疫功能檢測(cè)在乳腺癌臨床分期及預(yù)后評(píng)估中的價(jià)值分析[J].中國(guó)現(xiàn)代醫(yī)生，2019，57（12）：124-126.

[18] ?程楓，朱磊，陳歡，等.富含半胱氨酸分泌性酸性蛋白在乳腺癌組織中的表達(dá)及其臨床意義[J].中國(guó)臨床藥理學(xué)雜志，2017，33（1）：18-20.

[19] ?Cook KL，Soto-Pantoja DR，Clarke PA，et al. Endoplasmic reticulum stress protein GRP78 modulates lipid metabolism to control drug sensitivity and anti-tumor immunity in breast cancer [J]. Cancer Res，2016，76（19）：5657-5670.

[20] ?郭崇勇，丁寶忠，李柏成，等.三陰性乳腺癌組織中ALDH1、TGF-β_1蛋白的表達(dá)變化及其對(duì)預(yù)后的影響[J].山東醫(yī)藥，2017，57（46）：61-63.

[21] ?曾榃倫，呂錚，崔久嵬，等.腫瘤浸潤(rùn)淋巴細(xì)胞在三陰性乳腺癌療效預(yù)測(cè)及預(yù)后評(píng)估中作用的研究進(jìn)展[J].中國(guó)醫(yī)藥，2018，13（7）：1103-1106.

[22] ?周玉冰，殷德濤，李朵璐，等.細(xì)胞周期蛋白依賴性激酶11在乳腺癌組織中的表達(dá)及臨床意義[J].中華實(shí)驗(yàn)外科雜志，2016，33（3）：639-642.

（收稿日期：2019-08-21 ?本文編輯：顧家毓）